Drugs Affecting Bone Mineralization Flashcards

1
Q

key molecule that causes formation, activation and maintenance of osteoclasts

A

NF-kB ligand RANKL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The three MAJOR regulators of calcium homeostasis

A

PTH, vitamin D and FGF-23

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

PTH action in gut, kidney, and overall (on Ca and phosphorus)

A

PTH acts on the kidneys to increase calcium reabsorption and but it decreases phosphorous reabsorption in the kidney.

PTH works in the gut to increase BOTH calcium and phosphorous to reabsorption.

The net effect of PTH is to increase serum calcium and decrease serum phosphorous.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is Teriparatide (Forteo)

A

a subunit of amino acids 1-34 of human PTH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mechanism of action of Teriparatide (Forteo)

A

PTH has been shown to stimulate osteoblastic bone formation with intermittent PTH treatment. Teriparitide stimulates osteoblastic bone formation although the mechanism is not well understood. Thus Teriparatide has an anabolic effect on bone by increasing bone mass, structural integrity and strength.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Side effects of Teriparatide (Forteo)

A

mild hypercalcemia, and orthostatic hypotension.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the drug of choice for osteoporosis?

A

Teriparatide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Steps in Vitamin D activation

A

Vitamin D is hydroxylated in the liver to form 25-hydroxyvitamin D which is also called calcifediol calcidiol. Next, in kidney, 25-hydroxyvitamin D is further converted to 1,25-hydroxyvitamin D. This activated form of vitamin D is called calcitriol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is inactivated vitamin D and where is it stored?

A

vitamin D is stored in the liver as 25 -hydroxyvitamin D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the active form of vitamin D and what enzyme creates it

A

the active form of vitamin D occurs by 1-a hydroxylase in the kidney to form 1,25 -hydroxy vitamin D.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does vitamin D lead to reabsorption in the GI system

A

Vitamin D metabolites increase absorption of dietary calcium and phosphorous by stimulating the synthesis of many brush border proteins that increase uptake across the GI mucosa, leading to an increase in serum calcium concentration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Disorders where treatment is vitamin D

A

One of the primary treatment indications is vitamin D deficiency. It also is effective in the treatment of rickets and osteomalacia. Vitamin D is also used in the treatment of hypocalcemia. and hypoparathyroidism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the main role of FGF-23

A

The main role of FGF-23 is to inhibit 1,25 hydroxy vitamin D formation in the kidney and phosphate reabsorption in the kidney.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the main functions of calcitonin

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is calcitonin used for clinically

A

Calcitonin is used to lower plasma calcium and phosphorous concentrations in patients with hypercalcemia due to decreased bone resorption. However, the use of calcitonin is limited for this purpose long-term due to the “calcitontin escape” occurs within a few days and likely due to downregulation of receptors. Calcitonin is also effective in disorders of increased skeletal remodeling, such as Paget’s disease and osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What impact do glucocorticoids have one bone

A

Excess glucocorticoid levels decrease renal calcium reabsorption, interfere with intestinal calcium absorption, stimulate PTH secretion and stimulate osteoclastogenesis through RANKL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Main use of estrogen

A

The principal therapeutic application for estrogen is in the treatment and/or prevention of postmenopausal osteoporosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are SERMs and which is the most common

A

Selective estrogen receptor modulators, raloxifene

19
Q

How does raloxifene work

A

SERMs work by stimulating certain estrogen receptors and inhibiting other estrogen receptors. Raloxifene stimulates bone estrogen receptors and inhibits breast and uterine estrogen receptors. Raloxifene also increases bone mineral density by inhibiting bone resorption through effects on cytokines and RANKL.

20
Q

Side effects of raloxifene

A

raloxifene increases the risk of stroke, pulmonary emboli, and deep vein thrombosis.

21
Q

Mechanism of bisphosphonates

A

They form a three-dimensional structure capable of chelating divalent cations such as calcium. Bisphosphonates have a strong affinity for bone and especially target bone surfaces undergoing remodeling.

The enzyme-resistant analogues of pyrophosphate inhibit osteoclast function. Bisphosphonatesincrease bone density by inhibiting bone resorption, and osteoclastic function. Bisphosphonates become incorporated into the bone matrix and ingested by osteoclasts, promoting osteoclasts apoptosis.

22
Q

When is bisphosphanate indicated

A

Current guidelines recommend oral bisphosphonates first line for primary and secondary prevention of fractures. Additionally, bisphosphonates are indicated for osteoporosis and postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, paget’s disease, and bone metastases and cancer-induced hypercalcemia

23
Q

Bisphosphonates side effects

A

Bisphosphonates cause gastric and esophageal irritation. A very rare, but quite serious, side effect of bisphosphonates is osteonecrosis of the jaw.

24
Q

Contraindications for bisphosphonates

A

Contraindications to the administration and use of bisphosphonates include decreased renal function, esophageal motility disorder and peptic ulcers.

25
Q

Mechanism of denosumab

A

Denosumab (Prolia or XGEVA) is a monoclonal antibody. Its primary mechanism of action is that it binds to and prevents the action of RANKL. If you need to review the action of RANKL, go back to PAGE 2 of this learning activity. Remember since RANK ligand stimulates bone resorption, inhibition of RANK ligand would favor overall bone building as osteoclast activity would be less than osteoblast activity.

26
Q

Indications for denosumab

A

dications for the use of denosumab include the treatment of postmenopausal women or men with osteoporosis at high risk for fracture. Treatment is also indicated to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer or in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

27
Q

Contraindications for denosumab

A

Contraindications to denosumab includes hypocalcemia.

28
Q

Side effects of denosumab

A

Hypocalcemia can occur with treatment. Like bisphosphonates, osteonecrosis of the jaw has been reported with denosumab (Prolia).

29
Q

Mechanism of gallium nitrate

A

Gallium nitrate acts by inhibiting resorption through the inhibition of osteoclast activity. By preventing the activity of osteoclasts, gallium nitrate can successfully decrease serum levels of calcium. Gallium nitrate is given as an IV infusion.

30
Q

Clinical indications for gallium nitrate

A

Gallium nitrate is currently FDA approved for the management of hypercalcemia of malignancy.

31
Q

Side effect of gallium nitrate

A

nephrotoxicity

32
Q

Contraindication for gallium nitrate

A

severe kidney disease.

33
Q

Mechanism of calcimetics - Cinacalcet (Sensipar)

A

Cinacalcet activates the Calcium-sensing receptor (CaSR) in the parathyroid gland. Recall that the calcium sensing receptor is expressed on parathyroid cells, bone and kidneys and senses the fluctuations of calcium. Activation of the CaSR increases intracellular calcium resulting in inhibition of PTH secretion via negative feedback.

Ultimately inhibits PTH

34
Q

Indications for cinacalcet

A

Cinacalcet is approved for the treatment of secondary hyperparathyroidism in chronic kidney disease. It is also indicated for the treatment of parathyroid carcinoma and primary hyperparathyroidism in patients who are unable to undergo surgical resection of the parathyroid.

35
Q

Contraindications for cinalcalcet

A

patients with hypocalemia

36
Q

Side effects of cinalcalcet

A

dizziness, myalgia, nausea, vomiting, and hypoparathyroidism.

37
Q

Mechanism for calcylitics

A

Calcilytics are a calcium sensing receptor (CaSR) antagonist. By inhibiting the action of the CaSR, PTH secretion is stimulated

38
Q

Indication for calcylitics

A

have potential use for the short term stimulation of PTH secretion to have increase in bone formation, similar to the intermittent use of Teriparatide.

39
Q

Mechanism for Furosemide (Lasix)

A

Furosemide inhibits sodium reabsorption in the ascending limb of the loop of henle. Calcium reabsorption is coupled to sodium reabsorption in the loop. Sodium infusion leads to increase sodium loss and increase calcium loss. The net effect of furosemide is to decrease serum calcium levels by excreting calcium in the urine.

40
Q

Indications for furosemide

A

Hypercalcemia

41
Q

Example of thiazide diuretic

A

Hydrochorothiazide (Diurel)

42
Q

Mechanism of hydrochlorothiazide

A

Primary function is reducing renal calcium excretion. Calcium reabsorption occurs at the distal tubule in the kidney. Thiazides diuretics may increase the effectiveness of PTH in stimulating reabsorption of calcium by the renal tubules. They may also act on calcium reabsorption secondarily by increasing sodium reabsorption in the proximal tubule. The net effect is a decrease in calcium excretion in the urine. This could cause an increase in serum calcium levels since urine calcium excretion is reduced.

43
Q

Indications for hydrochlorothiazide

A

Hydrochlorothiazide is indicated for idiopathic hypercalciuria since they effectively reduce the hypercalciuria and incidence of stone formation.

44
Q

Contraindications for hydroxycholorthiazide

A

Since thiazide diuretics decrease urine calcium excretion, they are contraindicated in the treatment of hypercalcemia.